TELA Bio Provides Q2 Results and Updated Slide Deck to Investors

Rhea-AI Filing Summary

TELA Bio, Inc. furnished a press release reporting its financial results for the quarter ended June 30, 2025 and provided an updated corporate slide deck for investor meetings. The Form 8-K identifies the relevant disclosure items as Item 2.02 (results of operations and financial condition) and Item 7.01 (Regulation FD disclosure), and lists exhibits including the press release (Exhibit 99.1), the slide deck (Exhibit 99.2) and the Inline XBRL cover page (Exhibit 104). The filing notes these materials are furnished, not filed, and the document is signed by CEO Antony Koblish. The company’s common stock trades on Nasdaq under the symbol TELA and the registrant indicates emerging growth company status.

Positive

• Furnished a press release announcing financial results for the quarter ended June 30, 2025 (Exhibit 99.1)
• Provided an updated corporate slide deck for investor meetings (Exhibit 99.2)

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine earnings disclosure; no financial figures included in this filing—materials are furnished for investor review.

The Form 8-K discloses that TELA furnished a press release with quarterly results and an updated investor slide deck, but it does not include the underlying financial statements or metrics within the filing itself. Because the materials are marked as "furnished, not filed," they carry standard disclosure intent but limited Section 18 liability. Investors should review Exhibits 99.1 and 99.2 for details; the 8-K alone provides notice of the update rather than substantive financial data.

Corporate Governance Expert

TL;DR: Standard disclosure practice; Regulation FD slide deck provided and CEO attested to the filing—no governance red flags in this form.

The 8-K records an update under Regulation FD and furnishes a slide deck for investor presentations, reflecting routine investor communications. The filing explicitly states the materials are furnished rather than filed, which limits incorporation and liability under Section 18. The form is signed by the CEO, indicating authorized disclosure. The document also confirms the issuer’s Nasdaq listing (ticker TELA) and emerging growth company status, which can affect disclosure transition provisions.

false 0001561921 0001561921 2025-08-11 2025-08-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2025

TELA Bio, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39130		45-5320061
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1 Great Valley Parkway, Suite 24 Malvern, Pennsylvania		19355
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (484) 320-2930

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		TELA		Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2025, TELA Bio, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

On August 11, 2025, the Company updated information reflected in a corporate slide deck, which representatives of the Company will use in various meetings with investors from time to time. A copy of the presentation is attached hereto as Exhibit 99.2, and incorporated herein by reference.

The information furnished pursuant to Item 7.01, including Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being furnished herewith:

Exhibit No.		Document
99.1		Press Release of TELA Bio, Inc., dated August 11, 2025.
99.2		Corporate Slide Deck, dated August 11, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TELA BIO, INC.
	By:	/s/ Antony Koblish
	Name:	Antony Koblish
	Title:	Chief Executive Officer and Director

Date: August 11, 2025

FAQ

What did TELA report in this Form 8-K?

The company furnished a press release announcing financial results for the quarter ended June 30, 2025 and an updated corporate slide deck for investor meetings.

Are the press release and slide deck filed or furnished?

The Form 8-K states the press release (Exhibit 99.1) and slide deck (Exhibit 99.2) are furnished, not filed, and therefore are not incorporated by reference.

Which exhibits are included with the filing?

Exhibit 99.1 is the press release, Exhibit 99.2 is the corporate slide deck, and Exhibit 104 is the Inline XBRL cover page.

Which disclosure items does this Form 8-K address?

The filing references Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Exhibits).

Who authorized or signed the Form 8-K?

The Form 8-K is signed by Antony Koblish, Chief Executive Officer and Director.